| Mar 3, 2026 | Poplar Therapeutics | $45.0M Series A Extension | DAN Lyons | RA Capital Management, SR ONE, Vida Ventures |
| Feb 3, 2026 | Skyryse | $300.0M Series C | Autopilot | Atreides Management, BAM Elevate, Baron Capital Group, Durable Capital Partners, Fidelity Management & Research Company, Positive SUM, Qatar Investment Authority, Rokos Capital Management, Woodline Partners |
| May 1, 2024 | Zenas BioPharma | $200.0M Series C | SR ONE, TIM Xiao, NEA, Norwest Venture Partners | Vivo Capital, Enavate Sciences, Fairmount, Hermes GPE, Longitude Capital, Pivotal BioVenture Partners, Quan Capital, Rock Springs Capital, Superstring Capital, Wellington Management |
| Feb 15, 2024 | Freenome | $254.0M Other Equity | Matt Sause | American Cancer Society, Andreessen Horowitz, ARK Invest, Bain Capital Life Sciences, Data Collective, Eventide Asset Management, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Mark A. Gardner, RA Capital Management, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates |
| Feb 14, 2023 | Checkerspot | $55.0M Series C | ArrowMark Partners | — |
| Jan 1, 2022 | Simcha Therapeutics | $40.0M Series B | SR ONE | Westlake Village BioPartners, BVF Partners, Logos Capital, Rock Springs Capital, Samsara BioCapital |
| Dec 1, 2021 | Freenome | $300.0M Series D | Ellen Hukkelhoven, Peter Kolchinsky | Anzu Partners, Ameena EL Bibany, Vasudev Bailey, ARTIS Ventures, Asset Management Ventures, Bain Capital Life Sciences, Cofounders Capital, Merck Global Health Innovation Fund, Polaris Partners, Section 32, Anne Wojcicki, Timothy A. Springer, Andreessen Horowitz, Brightedge Ventures, Byers Capital, Catalio Capital, Data Collective, Eventide Asset Management, Farallon Capital Management, Fidelity Management & Research Company, GV, HBM Healthcare Investments, Intermountain Ventures, Janus Henderson Investors, Kaiser Permanente, Logos Capital, Novartis, Polaris Partners, Pura Vida Investments, Ridgeback Capital Investments, Thomas Schinecker, Rock Springs Capital, Sands Capital, Soleus Capital, Suvretta Capital Management, T. Rowe Price Associates |
| Nov 9, 2021 | Arbor Biotechnologies | $215.0M Series B | Frank YU, Chen YU, Temasek | ARCH Venture Partners, Deep Track Capital, GreatPoint Ventures, Illumina Ventures, Janus Henderson Investors, Logos Capital, ONO Venture Investment, Piper Heartland Healthcare Capital, Ridgeback Capital Investments, Section 32, Surveyor Capital, TAO Capital Partners, Tekla Capital Management, T. Rowe Price Associates, Vertex, Woodline Partners |
| Nov 8, 2021 | Fyllo | $40.0M Series C | Kristopher Koka | Arcadian Capital Management, JW Asset Management, K2 Asset Management, Longview Capital Advisors, Phyto Partners, Salveo Capital |
| Oct 1, 2021 | Skyryse | $200.0M Series B | Fidelity Management & Research Company, ROB Broggi | Alumni Ventures, C2 Investment, Embedded Ventures, Gumi Cryptos Capital, Infinite Capital, Mechanism Capital, Preston Werner Ventures, Valhalla Capital, WestCap, Kelvin Beachum JR., Dmitry Balyasny, Laurence A. Tosi, Eclipse Ventures, Fontinalis Partners, Fortistar, K3 Ventures, Raptor Group, Republic Capital, Rosecliff Ventures, SV Pacific Ventures, Venrock |
| Sep 20, 2021 | SmartLabs | $250.0M Series B | ArrowMark Partners | Breed's Hill Capital, Conversion Venture Capital, Falcon Investment Advisors, Winslow Capital |
| Jun 23, 2021 | Tvardi Therapeutics | $74.0M Series B | 683 Capital Management, ArrowMark Partners, Palkon Capital, Jamie Mcnab | Sporos Bioventures |
| Apr 1, 2021 | Invivyd | $340.0M Series C | Peter Kolchinsky | .406 Ventures, Abingworth, Eclipse Ventures, Flare Capital Partners, Foresite Capital, General Atlantic, GV, LUX Capital, Mithril Capital Management, OrbiMed, Polaris Partners, Sofinnova Investments, Westlake Village BioPartners, Adimab, Fidelity Management & Research Company, Hermes GPE, Omega Funds, Polaris Partners, Population Health Partners, Premji Invest, Redmile Group |
| Mar 23, 2021 | Dataminr | $475.0M Series F | — | Eden Global Partners, IVP, Lurra Capital, Morgan Stanley, MSD Capital, Reid Hoffman, Valor Equity Partners |
| Mar 1, 2021 | Amunix | $120.0M Series B | Viking Global Investors | Frazier Healthcare Partners, Avidity Partners, Bain Capital Life Sciences, BlackRock, Caas Capital Management, Casdin Capital, Franklin Templeton, Janus Henderson Investors, Longitude Capital, Omega Funds, Polaris Partners, Redmile Group, Venrock |
| Dec 16, 2020 | Neurogene | $115.0M Series B | Oleg Nodelman | Alexandria Venture Investments, Ascendant BioCapital, Avidity Partners, BlackRock, Casdin Capital, Cormorant Asset Management, Janus Henderson Investors, Redmile Group, Samsara BioCapital |
| Aug 5, 2020 | Taysha Gene Therapies | $95.0M Series B | Fidelity Management & Research Company | BlackRock, Casdin Capital, Franklin Templeton, GV, Invus, Octagon Capital, PBM Capital, Perceptive Advisors, Sands Capital, Venrock |
| Aug 1, 2020 | Xometry | $75.0M Series E | Andrew Davis | Almaz Capital, Cabra VC, Karma Ventures, Trind Ventures, What IF Ventures, BMW I Ventures, Dell Technologies Capital, Henry Ellenbogen, Foundry Group, Greenspring Associates, Highland Capital Partners, Robert Bosch Venture Capital |
| Jun 16, 2020 | 4D Molecular Therapeutics | $75.0M Series C | Viking Global Investors | Amzak Health, Berkeley Catalyst Fund, BVF Partners, Casdin Capital, Chiesi Ventures, Michael Boyle, Longevity Vision Fund, Mirae Asset, Octagon Capital, Perceptive Advisors, Quad Investment Management |
| Jan 29, 2020 | Lyra Therapeutics | $30.0M Series C | Konstantin Poukalov | Intersouth Partners, North Bridge, Polaris Partners, RA Capital Management, Soleus Capital |
| Dec 17, 2019 | ArcherDX | $55.0M Series C | Michael Altman | Boulder Ventures, Driehaus Capital Management, Longwood Fund, PBM Capital, Redmile Group, Sands Capital, Soleus Capital |
| Apr 1, 2019 | SpringWorks Therapeutics | $125.0M Series B | Adam Stone | Bain Capital, Boxer Capital, BVF Partners, GlaxoSmithKline, HBM Healthcare Investments, Laurion Capital Management, LifeArc, OrbiMed, Pfizer, Samsara BioCapital, Surveyor Capital |
| Nov 1, 2018 | NextCure | $93.0M Series B | Michael YI, Stella XU | 5AM Ventures, Access Biotechnology, Canaan Partners, Connecticut Innovations, Endeavor Venture Funds, Nextech Invest, OrbiMed, RA Capital, Alexandria Venture Investments, BAY City Capital, Canaan Partners, Lilly Asia Ventures, NS Investment, Pfizer, Ping AN Ventures, Sofinnova Investments, Surveyor Capital, Taiho Ventures |
| Sep 26, 2018 | Lyra Therapeutics | $29.5M Series B | Michael Altman | Intersouth Partners, North Bridge, Polaris Partners, RA Capital Management, Soleus Capital |
| Aug 24, 2018 | Evolve | $80.0M Other Equity | T. Rowe Price Associates | Allen & Company, Annox Capital, Foxhaven Asset Management, PAR Capital Ventures, Winslow Capital |
